Cargando…
Development of favipiravir loaded PLGA nanoparticles entrapped in in-situ gel for treatment of Covid-19 via nasal route
In 2019 the emergence of SARS-COV-2 caused pandemic situation worldwide and claimed ∼6.4 M lives (WHO 2022). Favipiravir (FAV) is recommended as a therapy for Covid-19 which belongs to BCS class III with a short half-life of 2–5.5h. Thus, the objective of current study was the development of favipir...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745979/ https://www.ncbi.nlm.nih.gov/pubmed/36530548 http://dx.doi.org/10.1016/j.jddst.2022.104082 |